<DOC>
	<DOCNO>NCT01702480</DOCNO>
	<brief_summary>This single centre , 2 part study old subject . Part 1 ( Pharmacokinetic [ PK ] Assessment ) double blind , randomize , placebo-controlled 4-period crossover study investigate PK profile four different dos GSK2981710 . Eight subject receive single dose GSK2981710 10 gram ( g ) , 20 g , 30 g , 40 g placebo morning PK assessment ( every 0.5 hr 8 hrs post-dose ) throughout day period . Each subject complete total four dosing session 4 day PK assessments 2 week . The Part 1 PK data use dose selection pharmacodynamic ( PD ) assessment period Part 2 . If data Part 1 inconclusive , additional 8 subject may recruit Part 1 repeat ( possibly drop dos ) increase confidence . A subject 's total participation Part 1 study last maximum approximately 7 week include screen . Subjects complete Part 1 may screen eligibility enrol Part 2 . Part 2 ( PD Assessment ) double blind randomize , placebo-controlled 2-period crossover design 14-day treatment period investigate efficacy ( cognitive performance ) tolerability ( gastrointestinal [ GI ] side effect ) single daily dose GSK2981710 select Part 1 . Part 2 study include Screening period , two Baseline assessment ( 6-8 day Treatment period ) two 14-day treatment period separate minimum 7-day washout period follow-up visit 3 5 day . Approximately 50 80 subject randomize either GSK2981710 placebo . The PD assessment perform 6 occasion subject : 2 baseline ( 6 8 day Day 1 treatment period ) , post-dose Day 1 treatment period ass acute effect Day 15 treatment period ( day final dose ) ass chronic effect . A subject 's total participation Part 2 study last approximately 12 week include screening .</brief_summary>
	<brief_title>Effects Triglycerides Age-Related Cognitive Function Decline Older Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Male female individual age 55 year 80 year inclusive . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . Childbearing potential negative pregnancy test test visit . Body weight &gt; =50 kilogram ( kg ) males &gt; =40 kg female . Body mass index ( BMI ) range 18.0 29.9 kg/meter ( ) ^2 . Capable give write informed consent , include compliance requirement restriction list consent form . Sufficiently fluent English able understand write spoken instruction opinion investigator . Supine blood pressure 110/70 150/90 millimetre mercury ( mmHg ) inclusive screening . Patients current history hypertension control stable regimen least 3 month prior study asymptomatic include . 12 lead electrocardiogram ( ECG ) without clinically significant abnormality judge Investigator , QT interval correct use Bazett 's formula ( QTcB ) QT interval correct use Fridericia 's formula ( QTcF ) &lt; =450 millisecond ( msec ) Suitable cannulation adequate venous access Aspartate aminotransferase ( AST ) , Alanine transaminase ( ALT ) , alkaline phosphatase bilirubin &lt; = 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . For Part 2 : Performs cutoff level Wechsler logical memory test mean level performance young , healthy adult . For Part 2 : Otherwise normal neuropsychological performance indicate performance require level MINI Mental State Examination ( MMSE ) ( score 27 eligible ) . Previous current medical condition , judge Investigator consultation GSK Medical Monitor require , may compromise subject safety may interfere study procedure interpretation data.. Learning disability learn disorder . Current history Axis I psychiatric disorder determine MINI interview A drug dependence Diagnostic Statistical Manual Mental Disorders , Fourth ( DSMIV ) criterion within last 6 month assess Miniinternational neuropsychiatric interview ( MINI ) . A fall least 20 mm Hg systolic blood pressure within three minute stand upright screen A positive prestudy human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GlaxoSmithKline ( GSK ) Medical Monitor medication interfere study procedure compromise subject safety . History alcohol substance abuse dependence 6 month prior screen determine investigator . Abuse alcohol , define male , average weekly intake great 21 unit ( average daily intake great 3 unit ) , define female , average weekly intake great 14 unit ( average daily intake great 2 unit ) . One unit equivalent halfpint ( 220 milliliter [ mL ] ) beer 1 ( 25 mL ) measure spirit 1 glass ( 125 mL ) wine . Current smoker define regular use tobacco nicotinecontaining product within 6 month prior screen . Positive urine drug alcohol breath test screening test study visit . Lactating female pregnant female determine positive urine/serum human chorionic gonadotropin ( hCG ) test screening test study visit . Where participation study would result donation blood blood product excess 500 mL within 90 day period . The subject participate clinical trial receive investigational product within following time period prior test day current study : 90 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Lactose intolerant allergic milk soy product The subject diet include diet restricts modifies intake particular type food , e.g . carbohydrate , protein , fat , ketogenic diet . Fasting Triglycerides equal 4.5 millimoles per litre ; ( mmol/L ) screening Subject , investigator/designee 's judgement , pose significant suicide risk . Evidence serious suicide risk may include history suicidal behaviour and/or evidence suicidal ideation questionnaire e.g . type 4 5 Columbia Suicide Severity Rating Scale ( CSSRS ) last 6 month . History sensitivity allergy drug component thereof , allergy , , opinion investigator GSK Medical Monitor , contraindicate participation .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Consumer Healthcare</keyword>
	<keyword>Ketones</keyword>
	<keyword>Medium Chain Triglycerides</keyword>
	<keyword>Age relate cognitive decline</keyword>
	<keyword>GSK Nutrition</keyword>
</DOC>